Consensus Glaukos Corporation

Stocks

GKOS

US3773221029

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 00:00:02 07/11/2026 +03			5-day change	1st Jan Change
224.41 ^USD	+2.01%		-5.55%	+98.75%

11-06	Analyst recommendations: AMD, Cloudflare, Flutter Entertainment, Marriott…
11-04	Glaukos Insider Sold Shares Worth $10,618,980, According to a Recent SEC Filing	MT

Evolution of the Average Target: Glaukos Corporation

Evolution of the Target Price: Glaukos Corporation

Changes in Analyst Recommendations: Glaukos Corporation

c50d65.Zasn_l1QOKvIyYhHzUL8dgmNqu7gAdr7fI_kgPMK3Pk.B-53ywgjCO2ljMkojgqfAmX78rnVMI7MC9ul-bJe7L8S_mSnKCgNxfGWzQ~4842a46fd6247497566ba3f0d9b8d9a2

Analysts' recommendations: Glaukos Corporation

11-06	Analyst recommendations: AMD, Cloudflare, Flutter Entertainment, Marriott…
10-29	Needham Adjusts Price Target on Glaukos Corp to $251 From $201, Keeps Buy Rating	MT
10-29	Not All AI Billions Are Equal
10-29	Analyst recommendations: Boston Scientific, Hilton, Kla Corporation, Fortinet, Microsoft…
10-29	Truist Adjusts Price Target on Glaukos to $255 From $215, Maintains Buy Rating	MT
07-30	HC Wainwrights Adjusts Glaukos Price Target to $195 From $168, Maintains Buy Rating	MT
07-30	UBS Adjusts Price Target on Glaukos Corp to $172 From $150, Maintains Neutral Rating	MT
07-30	Truist Raises Price Target on Glaukos to $215 From $180, Keeps Buy Rating	MT
07-30	Needham Raises Price Target on Glaukos to $201 From $150, Keeps Buy Rating	MT
07-28	UBS Downgrades Glaukos to Neutral From Buy, $150 Price Target	MT
07-16	Truist Adjusts Price Target on Glaukos to $180 From $160, Maintains Buy Rating	MT
06-17	Needham Raises Price Target on Glaukos to $150 From $136, Keeps Buy Rating	MT
04-30	Truist Raises Price Target on Glaukos to $160 From $145, Keeps Buy Rating	MT
04-30	Needham Raises Price Target on Glaukos to $136 From $127, Keeps Buy Rating	MT
12-18	Truist Securities Adjusts Price Target on Glaukos Corp to $145 From $120, Maintains Buy Rating	MT
12-09	Needham Adjusts Glaukos Price Target to $125 From $117, Maintains Buy Rating	MT
27/10/25	Wells Fargo Upgrades Glaukos Corp to Overweight From Equalweight, Adjusts Price Target to $120 From $92	MT
22/09/25	Truist Trims Price Target on Glaukos to $120 From $126, Keeps Buy Rating	MT
31/07/25	UBS Adjusts Price Target on Glaukos Corp to $134 From $125, Maintains Buy Rating	MT
30/07/25	Glaukos beats Q2 sales estimates, raises 2025 guidance	RE
06/05/25	Analyst recommendations: Block, Chevron, Fortinet, Skechers, Palantir…
01/05/25	Truist Adjusts Price Target on Glaukos Corp to $135 From $140, Maintains Buy Rating	MT
11/04/25	Truist Cuts Price Target on Glaukos to $140 From $185, Keeps Buy Rating	MT
19/02/25	Mizuho Upgrades Glaukos Corp to Outperform From Neutral, Adjusts Price Target to $200 From $140	MT
31/12/24	Stifel Adjusts Price Target on Glaukos to $175 From $153, Keeps Buy Rating	MT

More recommendations

Medical Devices & Implants

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GLAUKOS CORPORATION					+8.04%
	ABBOTT LABORATORIES					+7.82%
	MEDTRONIC PLC					+2.77%
	STRYKER CORPORATION					+4.48%
	ESSILORLUXOTTICA					+11.41%
	CENCORA, INC.					+11.8%
	BECTON, DICKINSON AND COMPANY					-7.7%
	IDEXX LABORATORIES, INC.					+6.08%
	HOYA CORPORATION					+36.89%
	ALCON INC.					+20.39%
	Average					+10.20%
	Weighted average by Cap.					+8.32%